EyePoint, Inc. is under investigation by Pomerantz LLP for potential securities fraud following the announcement that its Phase 3 trial for DURAVYU™ failed to meet the primary endpoint of improved visual acuity compared to a competitor drug. The news caused EyePoint's stock to drop nearly 67% in one day. This probe could lead to legal action if wrongdoing is found, impacting investors and the company's future. Investors are advised to contact Pomerantz LLP for more information or to join the class action.
EyePoint, Inc. is currently under investigation for potential securities fraud following a failed Phase 3 trial. For readers following the health sector, here is Pluang's market snapshot as of Sep 25, 2026 04:41 WIB: out of 100 priced health-sector US stocks, 38 rose and 62 fell. Notable movers include FLNA at USD 0.86 with a 1-day change of -16.15%, ACAD at USD 22.36 down 12.07%, and TXG at USD 84.70 up 12.01%. Typical hold times range from 37 to 94 days with varying buy/sell order activity.
TD SYNNEX posted a record-breaking quarter in Q3 2026 with earnings and revenue surpassing expectations, driven by strong growth in its Hyve Solutions segment and AI infrastructure demand. Despite this, the stock dropped nearly 9% due to a nearly $1 ...
A crypto whale transferred 6,000 Ether (ETH), worth approximately $16.1 million, to five major cryptocurrency exchanges: OKX, Kraken, Gate, Bybit, and Binance. This large transfer places a significant amount of ETH on trading platforms, suggesting th...
Warren Buffett increased his stake in homebuilder Lennar to over 10% immediately after the company missed earnings and lowered its full-year delivery forecast. Despite Lennar's recent weak quarter, Buffett's move signals confidence in the long-term h...
TRON has exceeded $30 trillion in total transaction volume, marking its evolution into a high-throughput settlement network. Daily transactions exceed $30 billion, supported by over 405 million users and 15.6 billion processed transactions, mainly dr...
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
